Owkin and Tribun Health launch strategic partnership to accelerate access to AI solutions for diagnosis and pharma research
Owkin and Tribun Health announce a strategic partnership to advance the development and global deployment of Artificial Intelligence (AI) Diagnostic and Research solutions for pathology departments and pharma companies. The non-exclusive partnership will see the integration of Owkin’s groundbreaking AI diagnostics into Tribun Health’s ‘Best in KLAS’ software platform, CaloPix, expanding its portfolio of AI solutions. Moreover, Owkin customers and users will be able to benefit from Tribun Health’s fully integrated software platform for research that streamlines pathology data workflows. This research platform, called EyeDo, is the heir to the Keen Eye acquisition made last year.
Meriem Sefta, Owkin’s Chief Diagnostic Officer, said:
We’re thrilled to embark on this partnership with Tribun Health, to help scale global clinical and laboratory access to our ground-breaking AI solutions for biomarker screening, treatment response and patient outcome prediction. We aim to build upon the successful collaboration initiated with the PortrAIt consortium and together advance our shared mission of supporting healthcare providers in their digital transformation and improving outcomes through precision diagnostics.
Tribun Health's platform empowers diagnostic laboratories, pharmaceutical, and biotech manufacturers with cutting-edge tools for seamless management, analysis, and sharing of cellular images.
Jean-François Pomerol, CEO at Tribun Health, said:
In our relentless pursuit of supporting labs in their digital journeys, we proudly announce a transformative partnership that will accelerate our business. Adding Owkin's advanced algorithms to our third-party solutions portfolio aims to enhance workflows and improve pathologist diagnosis confidence as well as researcher efficiency which could ultimately accelerate personalized treatments for patients.
Owkin, powered by its extensive international academic research network, and deep experience in multimodal AI and image analysis, addresses clinically challenging and unmet medical needs with user-friendly solutions for digital pathology as part of its fullstack biotech strategy. Owkin’s AI diagnostic offering includes a first-in-class, CE-marked diagnostic that optimizes testing for microsatellite instability with routine H&E slides, MSIntuit CRC and a risk assessment tool for recurrence in early breast cancer, RlapsRisk BC. Owkin is also developing several other oncology based diagnostics to enable more accessible and streamlined diagnosis for precision therapies across the globe.
About Tribun Health
Tribun Health leads the field with AI-powered digital pathology solutions, transforming the way pathologists diagnose and treat disease. Our advanced technology, combined with clinical and informatics expertise, delivers unparalleled accuracy, speed, and efficiency in pathology.
Selected for the esteemed French Tech 2030 program, Tribun Health is a two-time Best in KLAS award winner (2022 & 2023), recognized for exceptional customer satisfaction. We continually innovate in digital pathology and prioritize customer success.
As pioneers in digital pathology workflow solutions, we offer image acquisition, storage, a web-based management system, AI-powered image analysis with deep and machine learning algorithms, remote case sharing with peer review (telepathology), reporting and exceptional professional services and customer care. For more information, visit Tribun Health’s website.
Owkin Contact:
Talia Lliteras
Product Marketing Director Diagnostics
Tribun Health Contact:
Lorine Marcoux
Marketing Manager
lmarcoux@tribun.health
+33 1 89 20 38 53
About Owkin
Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment.
We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
